DERM

Dermira, Inc.

DERM

Delisted

DERM was delisted on the 19th of February, 2020.

Back to rankings

Financial journalist opinion

Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.

Journey Medical Corporation to Present at the Emerging Growth Conference

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Journey Medical Corporation (NASDAQ:DERM ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Mayank Mamtani - B.

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Zacks Investment Research

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Zacks Investment Research

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company's recently launched treatment for the inflammatory lesions of rosacea in adults.

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

See News Rankings

Charts implemented using Lightweight Charts™